Your browser is no longer supported. Please, upgrade your browser.
Armata Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own75.38% Shs Outstand18.44M Perf Week1.71%
Market Cap102.29M Forward P/E- EPS next Y-1.15 Insider Trans0.00% Shs Float6.88M Perf Month-9.35%
Income-22.20M PEG- EPS next Q-0.32 Inst Own8.60% Short Float0.69% Perf Quarter-25.40%
Sales0.80M P/S127.86 EPS this Y45.70% Inst Trans0.38% Short Ratio1.99 Perf Half Y27.13%
Book/sh1.02 P/B4.09 EPS next Y-7.50% ROA-49.60% Target Price- Perf Year29.91%
Cash/sh0.39 P/C10.66 EPS next 5Y- ROE-83.20% 52W Range2.56 - 10.48 Perf YTD39.70%
Dividend- P/FCF- EPS past 5Y65.60% ROI- 52W High-60.21% Beta1.35
Dividend %- Quick Ratio1.60 Sales past 5Y11.60% Gross Margin- 52W Low62.89% ATR0.18
Employees59 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)40.13 Volatility1.64% 4.80%
OptionableNo Debt/Eq0.04 EPS Q/Q25.20% Profit Margin- Rel Volume0.18 Prev Close4.10
ShortableYes LT Debt/Eq0.00 EarningsMar 18 AMC Payout- Avg Volume23.91K Price4.17
Recom1.70 SMA20-0.73% SMA50-13.05% SMA2006.79% Volume4,187 Change1.71%
Jun-19-19Initiated Ladenburg Thalmann Buy $9
Mar-18-21 04:05PM  
Mar-17-21 04:01PM  
Mar-16-21 11:01AM  
Jan-27-21 07:01AM  
Dec-09-20 07:30AM  
Nov-16-20 11:10PM  
Nov-15-20 07:17AM  
Nov-12-20 04:05PM  
Oct-29-20 07:30AM  
Oct-26-20 07:30AM  
Oct-15-20 07:30AM  
Sep-29-20 07:30AM  
Sep-11-20 07:30AM  
Aug-13-20 04:05PM  
Jun-30-20 06:05AM  
Jun-17-20 07:30AM  
May-14-20 04:05PM  
Apr-28-20 08:00AM  
Mar-30-20 07:30AM  
Mar-19-20 04:05PM  
Mar-18-20 08:00AM  
Feb-13-20 08:00AM  
Jan-29-20 08:04AM  
Jan-28-20 07:00AM  
Nov-12-19 04:05PM  
Oct-31-19 10:52AM  
Oct-21-19 07:05AM  
Oct-16-19 07:05AM  
Oct-10-19 04:05PM  
Sep-19-19 07:05AM  
Sep-12-19 09:00AM  
Aug-14-19 04:05PM  
Aug-02-19 03:27PM  
Aug-01-19 10:30AM  
Jun-18-19 07:01AM  
Jun-03-19 07:01AM  
May-28-19 07:01AM  
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.